NO20084603L - Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet - Google Patents

Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet

Info

Publication number
NO20084603L
NO20084603L NO20084603A NO20084603A NO20084603L NO 20084603 L NO20084603 L NO 20084603L NO 20084603 A NO20084603 A NO 20084603A NO 20084603 A NO20084603 A NO 20084603A NO 20084603 L NO20084603 L NO 20084603L
Authority
NO
Norway
Prior art keywords
receptor agonist
compounds
beta2 adrenergic
adrenergic receptor
dialkylphenyl
Prior art date
Application number
NO20084603A
Other languages
English (en)
Inventor
Craig Husfeld
Mathai Mammen
Pierre-Jean Colson
Adam Hughes
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NO20084603L publication Critical patent/NO20084603L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Det beskrives nye forbindelser med formel I der R1 og R2 er som angitt i beskrivelsen, eller farmasøytisk akseptable salter eller solvater eller steroisomerer derav. Det beskrives videre farmasøytiske perparater og kombinasjoner omfattende slike forbindelser, fremgangsmåter og mellomprodukter for fremstilling av slike forbindelser, og metoder for bruk av slike forbindelser for f.eks. å behandle pulmonære forstyrrelser som kronisk obstruktiv pulmonær sykdom eller astma.
NO20084603A 2006-04-25 2008-10-30 Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet NO20084603L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25
PCT/US2007/009925 WO2007127196A2 (en) 2006-04-25 2007-04-24 DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Publications (1)

Publication Number Publication Date
NO20084603L true NO20084603L (no) 2008-11-19

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084603A NO20084603L (no) 2006-04-25 2008-10-30 Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet

Country Status (20)

Country Link
US (3) US7524965B2 (no)
EP (1) EP2010489B1 (no)
JP (1) JP2009541209A (no)
KR (1) KR20090005389A (no)
CN (1) CN101426764A (no)
AR (1) AR060647A1 (no)
AU (1) AU2007243481A1 (no)
BR (1) BRPI0710767A2 (no)
CA (1) CA2650530A1 (no)
CO (1) CO6140054A2 (no)
ES (1) ES2391584T3 (no)
IL (1) IL194334A0 (no)
MA (1) MA30556B1 (no)
MX (1) MX2008013555A (no)
NO (1) NO20084603L (no)
PE (1) PE20080094A1 (no)
RU (1) RU2008146383A (no)
TW (1) TW200811105A (no)
WO (1) WO2007127196A2 (no)
ZA (1) ZA200808817B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7528253B2 (en) * 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
MY149731A (en) * 2008-02-06 2013-10-14 Astrazeneca Ab Compounds
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
CN114409556A (zh) * 2022-01-28 2022-04-29 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006635A1 (fr) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
WO1995021820A1 (fr) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (en) * 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2007528416A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
US7528253B2 (en) * 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
KR20090005389A (ko) 2009-01-13
US8134006B2 (en) 2012-03-13
CN101426764A (zh) 2009-05-06
ES2391584T3 (es) 2012-11-28
EP2010489A2 (en) 2009-01-07
BRPI0710767A2 (pt) 2011-06-07
JP2009541209A (ja) 2009-11-26
US7524965B2 (en) 2009-04-28
WO2007127196A3 (en) 2007-12-21
US20090176833A1 (en) 2009-07-09
ZA200808817B (en) 2010-03-31
US7687521B2 (en) 2010-03-30
AU2007243481A1 (en) 2007-11-08
CO6140054A2 (es) 2010-03-19
RU2008146383A (ru) 2010-05-27
PE20080094A1 (es) 2008-02-17
IL194334A0 (en) 2009-08-03
MA30556B1 (fr) 2009-07-01
US20070249675A1 (en) 2007-10-25
US20100137603A1 (en) 2010-06-03
CA2650530A1 (en) 2007-11-08
EP2010489B1 (en) 2012-08-22
TW200811105A (en) 2008-03-01
WO2007127196A2 (en) 2007-11-08
MX2008013555A (es) 2008-11-04
AR060647A1 (es) 2008-07-02

Similar Documents

Publication Publication Date Title
NO20084603L (no) Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet
NO20054206L (no) Bifenylderivater
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
TN2012000139A1 (en) Cgrp receptor antagonists
NO20070588L (no) Piperidinderivater som NK1-antagonister.
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20083197L (no) Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2010018109A3 (en) Substituted aminotetralines
TW200720226A (en) Fluorinated derivatives of 4-(2-amino-1-hydroxiethyl)phenol as agonists of the β2 adrenergic receptor
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
CL2008003494A1 (es) Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion.
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
DK2197841T3 (da) Guanidinholdige forbindelser anvendelige som muscariniske receptorantagonister
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NO20063602L (no) Benzyl(iden)-laktam-derivater
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BR112012024785A8 (pt) antagonista do receptor de cgrp
WO2010018112A3 (en) Monoaryl aminotetralines
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
WO2009118765A8 (en) Novel monoamine re-uptake inhibitor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application